CR Group L.P. 4
4 · T2 Biosystems, Inc. · Filed May 13, 2024
Insider Transaction Report
Form 4
Capital Royalty L.P.
10% Owner
Transactions
- Conversion
Common Stock
2024-05-09+1,716,048→ 4,595,977 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series A Preferred Stock
2024-05-09−17,160.48→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (1,716,048 underlying) - Conversion
Common Stock
2024-05-09+108,752→ 4,704,729 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Conversion
Series B Preferred Stock
2024-05-09−10,875.25→ 0 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.)→ Common Stock (108,752 underlying)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock converted into 100 shares of Common Stock for no additional consideration and has no expiration date.
- [F2]CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
- [F3]Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration and has no expiration date.